FDA grants label update for BMS Sprycel
This article was originally published in Scrip
Executive Summary
The US FDA has approved a label update of Bristol-Myers Squibb's anticancer drug Sprycel (dasatinib), to include three-year first-line efficacy and safety data in patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.